Impaired ultraviolet-B-induced cytokine induction in xeroderma pigmentosum fibroblasts.

Xeroderma pigmentosum is a rare, autosomal recessive disease in which patients develop excessive solar damage at an early age and have a 1000-fold increased risk of developing cutaneous neoplasms. Xeroderma pigmentosum can be classified into seven complementation groups (A-G) with defects in different DNA nucleotide excision repair genes. Xeroderma pigmentosum patients also have impaired immune function including reduced natural killer cell activity and impaired induction of interferon-gamma. We hypothesized that altered cytokine induction may contribute to the immune defect in xeroderma pigmentosum patients. We examined cytokine mRNA expression after ultraviolet B irradiation using reverse transcriptase polymerase chain reaction in fibroblasts derived from five xeroderma pigmentosum patients in complementation groups A, C, and D and in complemented XP-A and XP-D cells. Cytokines interleukin-1beta and interleukin-6 displayed impaired ultraviolet B induction whereas interleukin-8 had normal induction in the xeroderma pigmentosum fibroblasts. Stable complementation of XP-A and XP-D cell lines increased ultraviolet-B-induced interleukin-1beta and interleukin-6 expression. These results demonstrate a deficient response of xeroderma pigmentosum fibroblasts to ultraviolet B in terms of cytokine interleukin-1beta and interleukin-6 induction but normal interleukin-8 induction and exhibit a role for DNA repair in cytokine induction.

Interleukin-1 receptor antagonist suppresses contact hypersensitivity.

Interleukin-1 receptor antagonist (IL-1ra), a naturally occurring inhibitor of interleukin-1 (IL-1), blocks IL-1 binding to its receptors but has no agonistic activity. IL-1 is thought to play an important role in contact hypersensitivity (CHS), although the effects of exogenously administered IL-1 in CHS have been somewhat controversial. To clarify the role of IL-1 in CHS, we studied the effect of IL-1 receptor blockade using exogenous IL-1ra and evaluated these effects on CHS. We examined the in vivo effects of local administration of recombinant human IL-1ra in the murine CHS model. Local injection of IL-1ra to sensitized BALB/c mice just before challenge with dinitrofluorobenzene resulted in a significant reduction in the intensity of CHS responses, assessed by ear swelling. A dose-response study revealed that maximal inhibition of ear swelling (36% to 43%) was observed after intradermal injection of IL-1ra at doses of 10 to 100 micrograms/ear. This reduction in ear swelling in IL-1ra-injected ears consisted of less inflammatory cell infiltration and decreased edema in the dermis compared with controls. Suppression of CHS was observed when IL-1ra was applied in the 24-h interval preceding challenge with dinitrofluorobenzene, whereas no suppressive effect was observed when IL-1ra was applied 48 h before or after the challenge. Local administration of IL-1ra to naive mice 5 h before sensitization also suppressed CHS responses. However, IL-1ra injection did not suppress phenol-induced inflammation. These results suggest that IL-1ra is an effective inhibitor of both the sensitization and elicitation phases of CHS expression in mice, thus emphasizing the role of IL-1 as an immunologic potentiator of responses associated with CHS.

Imiquimod, a topical immune response modifier, induces migration of Langerhans cells.

Langerhans cells are bone marrow derived dendritic cells that represent the major antigen-presenting cells in the skin. Langerhans cells take up and process antigen within the epidermis and present processed antigen to T lymphocyte in the regional lymph nodes and thus form an integral part of the cutaneous immune response. The cutaneous immune response can be modified by a number of pharmacologic agents, including corticosteroids, cyclosporine, and retinoids as well as physical agents, such as ultraviolet light. For the most part these agents act by suppressing immune function. A topical immune response modifier, imiquimod has been shown to enhance the cutaneous immune response. Imiquimod has anti-viral and anti-tumor effects in animal models and has been approved for the topical treatment of external genital and perianal warts in humans. The biologic activity of imiquimod in part is due to its effect as a cytokine inducer. Preliminary data suggested that imiquimod could have an effect on Langerhans cells. In order to clarify this effect on Langerhans cells, we examined Langerhans cell morphology and migration in imiquimod-treated skin. The density of Ia + cells decreased 2 d after treatment, falling to approximately 43% by day 10. The Ia positive in cells remaining in the skin appeared larger and more dendritic suggesting an activated state. ATPase staining of epidermal sheet confirmed the decreased number of Langerhans cells. To clarify status of Langerhans cells, the activation of B7 was examined. Activation of B7-1 or B7-2 was not detected. Imiquimod, however, did enhance Langerhans cell migration from skin to draining lymph nodes. This enhanced Langerhans cell migration was also associated with an enhanced allergic contact hypersensitivity. These results suggest that the mechanism of modulation of immune response by imiquimod is in part due to effects on Langerhans cells.

The expression and modulation of IFN-alpha and IFN-beta in human keratinocytes.

In addition to leukocytes and fibroblasts, the classic sources of human interferons (IFN), many other human cells are now known to be capable of producing IFN. Keratinocytes (KC) are abundant in the skin and provide the first line of defense against viruses and other noxious agents. Human KC are a potent source of cytokines and were implicated as forming IFN-like protein(s). We have investigated whether KC form IFN. We found that culture supernatants from unstimulated human KC did not contain detectable amounts of IFN-alpha or IFN-beta. However, those from KC activated with the potent IFN inducer, polyriboinosinic:polriboycytidylic acid (poly rI:rC), had appreciable antiviral activity, which studies with neutralizing sera showed to be caused by IFN-beta. In ELISA tests, we detected IFN-beta protein in the supernatants but not IFN-alpha protein. Nevertheless, reverse transcription PCR showed that both IFN-alpha and IFN-beta mRNA were upregulated in poly rI:rC-treated KC. The levels of these mRNA were also increased in KC exposed to ultraviolet B (UVB) irradiation, interleukin-1alpha (IL-1alpha), tumor necrosis factor-alpha (TNF-alpha), or lipopolysaccharide (LPS). These results show that IFN-beta is among the cytokines secreted from human KC and, together with IFN-alpha, may have a role in host defense mechanisms in the skin.

Costimulation with ultraviolet B and interleukin-1 alpha dramatically increase tumor necrosis factor-alpha production in human dermal fibroblasts.

Ultraviolet light, particularly in wavelengths of 290-320 nm (UVB), is known to induce cytokine synthesis in the skin. Cytokines act in a cascade fashion and can have synergistic or antagonistic actions on regulation of other cytokines. In this study, we sought to determine whether cotreatment with UVB and interleukin-1 alpha (IL-1 alpha) induces tumor necrosis factor-alpha (TNF-alpha) production synergistically by human dermal fibroblasts. UVB irradiation (200 J/m2) or IL-1 alpha (10 ng/ml) independently induced small amount of TNF-alpha (< 25 pg/ml) from human dermal fibroblasts. However, combined treatments with UBV and IL-1 alpha induced 30-40-fold higher levels of TNF-alpha (750 pg/ml) than with either UVB of IL-1 alpha treatment alone. This synergy was also seen with mRNA expression. Maximum synergistic effect was observed when IL-1 alpha was added immediately after irradiation. Considering the fact that UVB is capable of causing release of IL-1 alpha from human keratinocytes and approximately 10% of incident UVB penetrates to the level of dermal fibroblasts, our results suggest that UVB may act in a cascade fashion to induce inflammation by initial release of keratinocyte IL-1 alpha, which then synergizes with UVB on human dermal fibroblasts to significantly increase TNF-alpha production.

Effect of a novel topical immunomodulator, S-28463, on keratinocyte cytokine gene expression and production.

A new immunomodulating agent, imiquimod, has been reported to have antiviral and antitumor activities in animal models. S-28463 (4-amino-2-ethoxymethyl-alpha, alpha-dimethyl-1H-imidazo[4, 5-c]quinoline-1-ethanol), an analog of imiquimod, has more potent antiviral activity in animals than imiquimod. It has also been shown to be more potent at inducing cytokines in human blood in vitro. However, its precise role as an immunomodulator in the skin has not been determined. We investigated the effect of S-28463 on human keratinocyte (KC) production of interferon-alpha (IFN-alpha) and other proinflammatory cytokines, including interleukin (IL)-1alpha, IL-8, and tumor necrosis factor-alpha (TNF-alpha). Human KC were incubated with S-28463 at two concentrations (1 microgram/ml and 10 micrograms/ml) for 6 h. Cytokine gene expression was analyzed by reverse-transcriptase PCR. In human KC, S-28463 stimulated significant increases in IFN-alpha mRNA at both concentrations. IL-1alpha mRNA increased 1.4-fold at 10 micrograms/ml. IL-8 mRNA was upregulated 2.5-fold at 10 micrograms/ml. Twenty-four hours after treatment, IL-1 alpha, IL-8, and TNF-alpha protein were increased, but IFN-alpha was below the level of detection. These results suggest that in the skin, S-28463-induced-IL-1 alpha, IL-8, and TNF-alpha production may be involved in the immunomodulating action of S-28463.

Age-related changes in contact photosensitivity differ among mouse strains.

There are differences among mouse strains in the age-related changes in reactivity to the contact photosensitizer tetrachlorosalicylanilide (TCSA). We found a tendency to lower reactions in older mice, with some strains showing declines from an early age (BALB/cJ, MRL/MpJ +/+, MRL/MpJ lpr/lpr and SJL/J). Others had increasing reactions until about 30-50 weeks of age before declining (DBA/1J, C3H/HeJ, and A/J) and one strain (C57BL/6J) had increased reactivity with age. There are also differences in the role of cyclophosphamide-sensitive T-suppressor cells in these age-related changes. In some mouse strains, BALB/cJ, C57BL/6J, A/J, DBA/1J and C3H/HeJ, age-related changes in reactivity to TCSA are independent of changes in cyclophosphamide-sensitive suppressor cells. In other strains, MRL/MpJ +/+, MRL/MpJ lpr/lpr and SJL/J, the development of cyclophosphamide-sensitive suppressor cells is responsible for the initial, though not later, stages of the age-related decline in reactivity.

The role of cis-urocanic acid in UVB-induced suppression of contact hypersensitivity.

Ultraviolet light B (UVB) is well recognized to suppress the contact hypersensitivity (CHS) response and it has been postulated that cis-urocanic acid (UCA) is a mediator of the immunosuppression. This study was designed to examine the effect of UCA on CHS and to clarify its role in UVB-induced immunosuppression in C57BL/6 mice. Intradermal injection of 0.5-50 micrograms cis-UCA into the ear 2 h before DNFB sensitization resulted in a 60-70% reduction of CHS assessed by ear swelling, whereas trans-UCA did not have a significant effect on CHS except at a high dose (50 micrograms) which showed a 20-40% suppression. Intraperitoneal injection of anti-cis-UCA antibody before administration of cis-UCA abrogated the suppression. To examine the effect of UCA on UVB-induced immunosuppression, some mice were pre-treated with anti-cis-UCA antibody and then exposed to UVB (960 J/m2). After 3 days the mice were sensitized either on the irradiated abdominal skin or on the unirradiated dorsal surface of the right ear followed by the challenge on the left ear. The CHS response was significantly suppressed in UVB-irradiated mice both locally (abdominal sensitization, suppression was 45%, P < 0.001) and systemically (ear sensitization, suppression was 53%, P < 0.0025). The CHS response was partially restored in both abdominal sensitized mice and ear sensitized mice by pre-treatment with anti-cis-UCA antibody. These results confirmed the immunosuppressive effects of cis-UCA on CHS and suggest that cis-UCA plays a role in UVB-induced local and systemic immunosuppression.

Optimization of tetrachlorosalicylanilide and ultraviolet A doses at sensitization and challenge for contact photosensitivity in the mouse.

We studied contact photosensitivity (CPS) to tetrachlorosalicylanilide (TCSA) in BALB/cJ mice with various doses of TCSA and UVA at sensitization and challenge. From these studies we recommend the following protocol: sensitization on days 0 and 1 with 50 microliters of 1% TCSA followed by 3 J/cm2 of UVA, and challenge on day 7 with 10 microliters of 3% TCSA followed by 6 J/cm2 of UVA. This gave an ear swelling response of 27.4 +/- 0.6 x 10(-3) (mean +/- standard error). We also demonstrated that there is reciprocity between volume and concentration of TCSA at sensitization but not between TCSA and UVA doses at sensitization.

Ultraviolet B light-induced suppression of contact sensitivity is not abolished by cyclophosphamide.

Dose responses for ultraviolet B light (UVB)-induced suppression of contact sensitivity were studied in mice, with and without cyclophosphamide (Cy) pretreatment, to investigate the role of Cy-sensitive suppression. Mice were irradiated on the back, sensitized on the abdomen, and challenged on the ears. Half of the mice were injected intraperitoneally with 200 mg/kg of Cy 3 days before being sensitized. Ultraviolet B light radiation reduced the ear swelling reactions in a linear relation to the log10 of the dose. Fifty percent suppression was shown by the computer-generated regression line at approximately 4.8 kJ/m2 of UVB radiation, with complete suppression at approximately 65 kJ/m2. In mice pretreated with Cy, ear swelling was increased, showing inhibition of a Cy-sensitive suppressive component of the contact sensitivity reaction. This Cy-sensitive component also was seen in mice treated with UVB, but with higher doses of UVB, there still was a UVB-dose-dependent decline in ear swelling in Cy pretreated mice, and there was complete suppression of reactions with the highest doses of UVB in the Cy-treated mice. Therefore, there is a second mechanism, not sensitive to Cy, that causes UVB-induced immune suppression.

Effects of contact sensitizers neomycin sulfate, benzocaine and 2,4-dinitrobenzene 1-sulfonate, sodium salt on viability, membrane integrity and IL-1 alpha mRNA expression of cultured normal human keratinocytes.

The toxic effect of three potential contact sensitization chemicals [the aminoglycosidic antibiotic neomycin sulfate, the local anaesthetic benzocaine and the primary sensitizer 2,4-dinitrobenzene 1-sulfonate, sodium salt (DNBS)], on cultured human keratinocytes was examined. The three chemicals were compared with respect to their cytotoxic potential (determined by crystal violet staining assay), their membrane disruptive potential ([3H]arachidonic acid release assay), and their effects on interleukin 1 alpha (IL-1 alpha) mRNA expression [reverse transcription-polymerase chain reaction (RT-PCR)]. At the concentrations used, neomycin sulfate (0.004-0.32%) and benzocaine (0.0165-0.165%) did not show relevant cytotoxicity or membrane perturbation. On the other hand, DNBS (0.001-1%) caused a significant dose-dependent cytotoxic response at concentrations higher than 0.1%, while the [3H]arachidonic acid release assay indicated absence of membrane perturbation activity in all the range of DNBS concentrations examined. The effects of the three sensitizers on IL-1 alpha mRNA expression were varied; neomycin sulfate caused a dose-dependent induction of IL-1 alpha mRNA, benzocaine did not significantly affect its signal, and DNBS suppressed IL-1 alpha gene expression.

Dose and timing studies for the optimization of contact sensitivity in the mouse.

We investigated the effectiveness of very low doses of the contact sensitizer dinitrofluorobenzene in sensitizing BALB/cJ mice. Surprisingly, the ear swelling reactions were greater with lower dinitrofluorobenzene doses, down to one-twentieth of doses commonly used. Although it is common practice to use much lower doses at challenge than at sensitization, we found greater reactions with lower doses at sensitization than at challenge. We also studied the timing of the development and waning of reactivity to dinitrofluorobenzene, dinitrochlorobenzene and oxazolone. Reactivity peaked at day 5 for dinitrofluorobenzene and dinitrochlorobenzene, and at day 3 for oxazolone. Reactivity waned by 3 weeks with dinitrofluorobenzene and oxazolone, and by day 7 with dinitrochlorobenzene. Pretreatment with cyclophosphamide caused a delay in the development and waning of reactivity.

A dose-response study of UVB-induced suppression of contact photosensitivity in the mouse.

A marked contact photosensitivity (CPS) response to 3,3',4',5 tetrachlorosalicylanilide (TCSA) plus UVA was induced in mice. Cyclophosphamide (Cy), given prior to sensitization, caused a further increase in ear swelling. When UVB radiation was given at a site distant from that used for sensitization it caused a dose-related suppression of CPS. Cy did not eliminate the UVB-induced suppression.

Dose response studies for UVA in contact photosensitivity to TCSA in the mouse.

We performed UVA dose response studies for contact photosensitivity (CPS) to 3,3',4',5-tetrachlorosalicylanilide (TCSA) in BALB/cJ mice using the back for induction and the ears for elicitation. The dose of TCSA was kept constant. The challenge procedure in non-sensitized mice produced a phototoxic response at 24 h after challenge. None of the 11 mice tested showed simple contact sensitivity (CS) to TCSA. Vigorous CPS responses were achieved with sensitization doses of UVA as low as 0.5 J/cm2 and the peak reaction occurred at 24 h after challenge. UVA sensitization doses less than 0.5 J/cm2 gave responses that were reduced in a dose-related manner and the peak response was delayed to 48 h or longer after challenge. The maximum elicitation dose of 6.0 J/cm2 UVA gave the greatest response and almost all ears showed vigorous reactions if the sensitization dose was 0.5 J/cm2 or greater. Lower elicitation doses gave lesser reactions in a dose-related manner. Cyclophosphamide (Cy) pretreatment increased the CPS reaction by about 50%.

The duration of contact photosensitivity to TCSA in the mouse.

We examined the course and duration of contact photosensitivity (CPS) to 3,3', 4',5-tetrachlorosalicylanilide (TCSA) in BALB/cJ mice. The doses of TCSA and UVA at sensitization and challenge were kept constant and the time between sensitization and challenge was varied between 4 days and 9 weeks. A small increase in ear swelling was seen at the 4-d challenge with a further increase at 5 d. The peak challenge response was reached at 7 d. Gradually decreased reactions were found at challenges 2,3 and 5 wk after sensitization and, at 7 and 9 wk challenges, sensitization was not detected. Resensitization of the 9-wk group, with challenge a week later, produced a good reaction though not a maximum one, thus the waning of sensitization was not due solely to active suppression.

Studies of the action spectrum for induction of photosensitivity to tetrachlorosalicylanilide in mice.

We have developed a new system, using ear swelling in mice, to study the action spectrum for the induction of photosensitivity to tetrachlorosalicylanilide (TCSA). Using narrow-band interference filters, we produced data for action spectra between 250 nm and 421 nm with doses of 0.5 J/cm2 and 0.2 J/cm2. We found that the higher dose generally produced greater reactions. The action spectrum was similar to the absorption spectrum for TCSA in the UVA region. The reduced responses in the UVB and UVC regions may be due to immunological suppression produced by these parts of the spectrum.

Assessment by mouse model of the ultraviolet A protective effect of topical sunscreens.

We have developed an animal model to assess the ultraviolet A (UVA) protective effect of topical sunscreens with the use of BALB/cJ mice in which contact photosensitivity to 3, 3', 4', 5 tetrachlorosalicylanilide had been induced. The mice were sensitized on the clipped dorsal skin and challenged on the ears. Changes in ear thickness after challenge were used to measure the degree of photosensitivity. The efficacy of two doses of each topical sunscreen was assessed by the degree of suppression of the contact photosensitivity response at challenge. Control studies were performed with the base of each sunscreen. Some but not all sunscreens that contained UVA-absorbing chemicals showed active suppression of contact photosensitivity in this test system. Several sunscreens gave greater suppression at 5 microliters/cm2 than at 2 microliters/cm2, which suggests a dose-related effect. One sunscreen, however, gave greater suppression at 2 microliters/cm2. Several of the bases tested also suppressed the contact photosensitivity response. An unexpected finding was an enhancement of the contact photosensitivity reaction by two of the bases tested.

The role of CD4 molecules in the induction phase of contact hypersensitivity cytokine profiles in the skin and lymph nodes.

We have previously demonstrated that CD4 gene-targeted mutant mice (CD4- mice) demonstrate hyporesposiveness in contact hypersensitivity (CHS) suggesting that CD4 molecules are required for optimal induction of CHS. In the present study, we wished to examine the mechanisms of this hyporesponsiveness, in particular, we examined whether cytokines were altered in the skin and lymph nodes of CD4- mice following exposure to the contact allergen dinitrofluorobenzene (DNFB). Cytokine mRNA in the ear skin and draining lymph nodes (DLN) were examined by reverse transcription-polymerase chain reaction (RT-PCR) at various times after sensitization. Skin cytokine patterns revealed that in normal mice, interleukin (IL)-2, interferon (IFN)-gamma and tumour necrosis factor (TNF)-alpha mRNA levels increased at 12 hr sensitization, whereas these cytokines were below the level of detection in CD4- mice. In the DLN of normal mice following the hapten application, sequential upregulation of cytokine mRNA including IL-1 alpha, IL-1 beta, IL-2, IL-4, IL-10, IFN-gamma and TNF-alpha was found. No change was seen for IL-1 alpha, IL-1 beta, IL-10 and TNF-alpha and IL-2, IL-4 and IFN-gamma mRNA levels were below the level of detection in DLN from CD4- mice following the hapten application. However, IL-1 beta, IL-2 and TNF-alpha mRNA levels of lymph node cells from CD4- mice could be upregulated by phorbol myristate acetate in vitro. Flow cytometry study has revealed that the number of Langerhans' cells (LC) in DLN of CD4- mice was similar to that of normal mice, thus, inferring that the alterations of cytokine milieu in the ear skin did not have a significant effect on LC migration to DLN. These results suggest that CD4 molecules are crucial for the induction of certain cytokines in the skin and in inducing sequential cytokine signals in DLN required for optimal development of CHS, but that these changes in cytokines do not effect LC migration.

The effect of VAS972 on allergic contact hypersensitivity.

BACKGROUND: Contact hypersensitivity (CHS) is a Th1-mediated immune response that can be down-regulated by immunosuppressive agents such as cyclosporine and environmental stimuli such as ultraviolet light. Recently, an immunomodulation therapy, VAS972, has been developed which is believed to down-regulate the Th1 arm of the immune response. This VAS972 involves modifying autologous blood by controlled exposure to the oxidizing agent ozone and UVC light, at an elevated temperature ex vivo. The processed blood is then administered by intramuscular injection. OBJECTIVE: To further evaluate the immune modulating effect of VAS972. METHODS: We examined the effect of VAS972 treatment on CHS. Contact hypersensitivity was induced with dinitrofluorobenzene (DNFB) in animals receiving VAS972- processed blood, control blood, or saline. A preliminary study was also conducted to evaluate the effect of plasma and cellular fractions of processed blood. RESULTS: Mice injected with VAS972-processed blood demonstrated a significantly lower (46%) CHS response than controls. Histologic examination of challenged ear skin from control mice displayed edema with a significant lymphocytic infiltration, whereas animals administered processed blood demonstrated a reduction in lymphocytic infiltration. Mice injected with either plasma or the cellular fraction of the VAS972-treated blood also demonstrated a significant suppression (49% and 41%, respectively). CONCLUSION: The results of this study demonstrated that VAS972 suppresses CHS and cellular infiltration. Furthermore, the plasma and cellular components of the VAS972 treatment were also able to induce immunosuppression. This further supports the hypothesis that VAS972 down-regulates the Th1 arm of the immune response.